Attitudes and Statistical Methods in Clinical Trials - PowerPoint PPT Presentation

1 / 21
About This Presentation
Title:

Attitudes and Statistical Methods in Clinical Trials

Description:

Armitage(1998) gives the definitions according to Schwartz and ... Increasing interest is reflected in literature and pharmaceutical companies. 21. References ... – PowerPoint PPT presentation

Number of Views:62
Avg rating:3.0/5.0
Slides: 22
Provided by: meiyi6
Category:

less

Transcript and Presenter's Notes

Title: Attitudes and Statistical Methods in Clinical Trials


1
Attitudes and Statistical Methods in Clinical
Trials
  • Meiyi Chen
  • April 25, 2005
  • Department of Statistics
  • University of Connecticut

2
Introduction
  • Two attitudes in clinical trials
  • Explanatory
  • Pragmatic
  • Statistical methods in clinical trials
  • Frequentist approach for explanatory attitude
  • Two approaches for pragmatic attitude
  • Bayesian approach
  • Intention-to-treat approach

3
Explanatory and Pragmatic Attitudes
Armitage(1998) gives the definitions according to
Schwartz and Lellouch (1967), The explanatory
attitude an attempt to understand precisely the
relative effects of alternative treatments when
administered under ideal conditions.It simulates
laboratory conditions, gives biological
information, studies principles of pharmacology
or physiology and assess efficacy. The Pragmatic
attitude a comparison of treatments made under
the less rigorous conditions likely to be found
in practice. It resembles the conditions of
normal clinical practice, focuses on the
question, "What is the better treatment in the
particular clinical circumstances of the patients
in the study?" and assess effectiveness The
following aspects in the design and analysis of a
clinical trial should be considered definition
of treatment regimens, assessment of results,
choice of subjects, method of comparison and
ethics.
4
Definition of Treatment Regimens
  • In explanatory approach, the treatment regimens
    are strictly defined
  • In pragmatic approach, the treatment regimens are
    loosely defined
  • For example, consider the treatment of cancer in
    which radiotherapy alone is to be compared with
    radiotherapy preceded by the administration of a
    drug which has no effect by itself but which may
    sensitize the patient to the effects of radiation
  • The explanatory approach requires a control group
    to have an initial 30-day period without drug
    treatment
  • The pragmatic approach starts radiotherapy
    immediately in the control group

5
Assessment of Results
  • The explanatory approach emphasizes on biological
    significance, such as tumour regression or
    biochemical changes.
  • The pragmatic approach emphasizes practical
    measures, such as back to work, decrease in pain
    and duration of survival.

6
Choice of Subjects
  • In the explanatory approach
  • Subjects may be highly selected
  • Tend to have "exclusive" eligibility criteria
  • Only patients who take medication according to
    the study protocol should be included in the main
    analysis
  • In the pragmatic approach
  • A more heterogeneous patient population is
    acceptable
  • Tend to have inclusive" eligibility criteria
  • All randomized patients would include in analyses
    called "intention-to-treat" analyses

7
An Example for Choice of Subjects
Studying a new analgesic in patients with
visceral pain related to cancer1. Patients must
have documented radiological evidence of a tumor
impinging on a hollow viscus corresponding to an
area where they complain of poorly localized,
crampy pain. Patients are ineligible if there is
a lesion of somatic tissues such as ribs or
abdominal wall, or if their pain complaint
includes superficial and steady pain.  2.
Patients are eligible if they have a diagnosis of
metastatic cancer and their primary complaint is
of crampy abdominal pain in the absence of
obvious gastrointestinal disorders unrelated to
cancer.   Question Which one is a pragmatic
approach? Answer 1. Explanatory
2.Pragmatic Source http//symptomresearch.nih.gov
/chapter_1/sec5/cmms5pg2.htm
8
Ethical Problems
  • Normally, explanatory approach must be done on
    animals, therapeutic trials on human subjects
    should be limited to pragmatic approach.
  • Lellouch and Schwartz (1971) described the two
    ethics of clinical trials between explanatory and
    pragmatic approaches
  • Individual ethics for explanatory approach
    interested in the individual patient.
  • Collective ethics for pragmatic approach
    emphasize the benefit to society, or to
    population of patients exposed to which treatment
    is chosen.
  • The modern clinical trial is a controlled
    experiment with efficient organization, careful
    plan and execution, and capability of
    interpretation by valid statistical analysis,
    such as stopping decision.
  • Individual patients are safeguarded by the use of
    informed consent, the provision for withdraw and
    the data and safety monitoring.

9
Method of Comparison
  • The classical testing of significance is
    appropriate for explanatory trials, concluding
    that a true difference exists only when the
    observed difference exceeds a threshold level
    which guarantees the required error probability
    ?.
  • For pragmatic trials, a decision from some form
    of decision theory, such as Bayesian and
    intention-to treat may be needed to decide which
    treatment is better.

10
Frequentist Vs Bayesian Methods in Clinical
Trials
David J Spiegelhalter etc., An Introduction to
Bayesian Methods in Health Technology Assessment,
BMJ, 319, 508-511 (1999)
11
Why Aren't Bayesian Methods More Widely Used in
Clinical Trials Research?
  • Bayesian analysis can be computer intensive and
    effective computational software are needed to
    perform Bayesian analysis.
  • BUGS project began in 1989
  • Few statisticians are proficient in the routine
    application of Bayesian analysis.

12
Bayesian Methods of Choice of Sample Size and
Allocation in Clinical Trials
  • Adcock (1997) gives a review of both Bayesian and
    frequentist methods on determining the overall
    sample size for clinical trials
  • Armitage (1989) suggests the use of a dynamic
    allocation method with a fixed number of patients
  • Lindley (1997) discusses utility functions which
    balance the cost with the effectiveness of the
    design

13
Bayesian Methods of Choice of Sample Size and
Allocation in Clinical Trials (Continued)
  • Tan and smith (1998) consider problems of choice
    of sample size and allocation using utility
    functions when utilities includes
  • Benefits and cost (suited to the drug developer)
  • Side-effects
  • Trade-off between benefit and side-effects

14
Intention-to-treat in Pragmatic Clinical Trials
  • The pragmatic attitude is often taken to be
    exemplified par excellence by the
    intention-to-treat approach to the analysis of
    results, whereby comparisons are made between the
    outcomes for the complete groups assigned to
    different treatment regimens, irrespective of the
    extent of departure from the treatment schedules
    laid down in the protocol.
  • ---- Peter
    Armitage (1998)

15
Why Should Intention-to-treat Be Used ?
  • Reasons including
  • The benefit of randomization are maintained
    because compliance or noncompliance occurs after
    randomization.
  • Excluding noncompliance can bias the treatment
    evaluation.
  • It simulate routine practice.
  • Possible counter-arguments
  • The extent of non-compliance may be different
    from that in routine practice, so the simulation
    of routine practice by non-compliance is dubious.
  • Using an explanatory approach is subject to
    selection bias, it might be better to accept such
    bias.
  • An intention-to-treat analysis is likely to
    underestimate true differences, because the
    non-compliers will dilute the effect from the
    compliers.

16
Analyzing Non-compliance in clinical trials
  • One very simple model stated in Sommer and Zeger
    (1991) supposed that the success proportions are
    known separately for compliers and non-compliers
    in the drug group.
  • Efron and Feldman (1991) provided a regression of
    the outcome variable on the compliance measure.
  • Sheiner and Rubin (1995) advocated the
    model-based analyses of efficacy, presenting
    intention-to treat limitation.

17
Analyzing Non-compliance in clinical trials
(Continued)
  • Rubin (1998) suggests
  • A test statistic is nominated a priori in a
    randomized experiment with non-compliance.
  • A generally uncontroversial model is posited for
    non-compliance under the null hypothesis.
  • Valid p-values can be obtained using
    randomization-based posterior-predictive
    distributions.

18
Conclusions
  • Two attitudes in clinical trial
  • Explanatory
  • Pragmatic
  • Methods to analyze clinical data
  • Frequentist
  • Bayesian
  • Intention to treat

19
Discussion
  • Which attitude is better?
  • Schwartz and Lellouch tends the explanatory and
    pragmatic attitudes correspond to a clear choice
    between two sorts of trial.
  • Armitage (1998) suggested that the two attitudes
    are likely to co-exist in any one trial.

20
Discussion(continued)
  • Which method of analysis should be used?
  • Considering noncompliance, the intention-to-treat
    is commonly used in analysis of randomized
    controlled trials, but it is inadequate.
  • Alternative methods include
  • Per protocol analysis compare outcomes only in
    those patients who are compliant.
  • As-treated analysis compares observed outcomes
    according to treatment received.
  • Classical methods used in randomized controlled
    trial include
  • Power calculation at design stage
  • Control type I error within sequential monitoring
  • Calculate p value and confidence intervals at the
    final analysis
  • Meta-analysis for pooling the results of multiple
    study
  • Bayesian method
  • More flexible and ethical
  • Elegant ways to hand multiple sub-studying
  • Provide conclusions in a suitable form for making
    decision
  • Increasing interest is reflected in literature
    and pharmaceutical companies.

21
References
  • Armitage, P. The search for optimality in
    clinical trials, International Statistical
    Review, 53, 15-24 (1985).
  • Armitage, P. Attitudes in Clinical Trials,
    Statistics In Medicine, 17, 2675-2683 (1998).
  • Schwartz, D. and Lellouch, J. Explanatory and
    pragmatic attitudes in therapeutic trials,
    Journal of Chronic Diseases, 20, 637- 648 (1967).
  • Tan, S. B. and Smith, A. F. M. Exploratory
    Thought on Clinical Trials with Utilities,
    Statistics In Medicine, 17, 2771-2791 (1998).
  • Sheiner, L. B. etc. Intention-to-treat analysis
    and the goals of clinical trials, Clinical
    Pharmacology and Therapeutics, 57, 6-15 (1995).
  • Spiegelhalter D. J. Bayesian Methods in Health
    Technology Assessment a Review, Health
    Technology Assessment, Vol. 4 No. 38 (2000).
Write a Comment
User Comments (0)
About PowerShow.com